Current Cardiology Reports

, Volume 10, Issue 3, pp 168–175 | Cite as

Mechanical support in acute and chronic heart failure

  • Andreas Brieke
  • Joseph ClevelandJr
  • JoAnn Lindenfeld
Article

Abstract

Heart failure (HF) is the leading cause of hospital admissions in the United States in people over the age of 65 years. Major advancements in the medical therapy of HF, combined with automatic implantable cardioverterdefibrillators and cardiac resynchronization therapy, have substantially reduced the mortality and morbidity of chronic HF, but mortality remains high, and the availability of donor hearts for transplantation is limited. Thus, there has been and continues to be a need for alternative therapies to support the failing heart. The development of mechanical pumps designed to assist or replace cardiac function started three decades ago with the National Heart, Lung, and Blood Institute’s request for proposals to develop an artificial heart. Significant progress has been made, with ventricular assist devices evolving from bulky extracorporeal devices to internalized miniaturized devices. Improvements in durability, thrombogenicity, ease of implantation, and patient selection have allowed expanding indications for these devices.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Rosamond W, Flegal K, Furie K, et al.: Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25–e146.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedGoogle Scholar
  3. 3.
    Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.PubMedCrossRefGoogle Scholar
  4. 4.
    Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349–1355.PubMedCrossRefGoogle Scholar
  5. 5.
    Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.PubMedCrossRefGoogle Scholar
  6. 6.
    Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.PubMedCrossRefGoogle Scholar
  7. 7.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  8. 8.
    Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057.PubMedCrossRefGoogle Scholar
  9. 9.
    Williams ES, Miller JM: Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol 2002, 40:1–18.PubMedCrossRefGoogle Scholar
  10. 10.
    Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:347–354.PubMedCrossRefGoogle Scholar
  11. 11.
    Mann DL, McMurray JJ, Packer M, et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594–1602.PubMedCrossRefGoogle Scholar
  12. 12.
    Chung ES, Packer M, Lo KH, et al.: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133–3140.PubMedCrossRefGoogle Scholar
  13. 13.
    Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325:1468–1475.PubMedGoogle Scholar
  14. 14.
    Uretsky BF, Jessup M, Konstam MA, et al.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990, 82:774–780.PubMedGoogle Scholar
  15. 15.
    Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883.PubMedCrossRefGoogle Scholar
  16. 16.
    Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225–237.PubMedCrossRefGoogle Scholar
  17. 17.
    Cleland JG, Daubert JC, Erdmann E, et al.: Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006, 27:1928–1932.PubMedCrossRefGoogle Scholar
  18. 18.
    Bristow MR, Saxon LA, Boehmer J, et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140–2150.PubMedCrossRefGoogle Scholar
  19. 19.
    Maybaum S, Mancini D, Xydas S, et al.: Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007, 115:2497–2505.PubMedCrossRefGoogle Scholar
  20. 20.
    George I, Xydas S, Mancini DM, et al.: Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support. J Heart Lung Transplant 2006, 25:1084–1090.PubMedCrossRefGoogle Scholar
  21. 21.
    Burkhoff D, Klotz S, Mancini DM: LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 2006, 12:227–239.PubMedCrossRefGoogle Scholar
  22. 22.
    Oz MC, Rose EA, Levin HR: Selection criteria for placement of left ventricular assist devices. Am Heart J 1995, 129:173–177.PubMedCrossRefGoogle Scholar
  23. 23.
    Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435–1443.PubMedCrossRefGoogle Scholar
  24. 24.
    Papaioannou TG, Stefanadis C: Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. ASAIO J 2005, 51:296–300.PubMedCrossRefGoogle Scholar
  25. 25.
    Ferguson JJ 3rd, Cohen M, Freedman RJ, Jr, et al.: The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol 2001, 38:1456–1462.PubMedCrossRefGoogle Scholar
  26. 26.
    Hochman JS, Buller CE, Sleeper LA, et al.: Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000, 36:1063–1070.PubMedCrossRefGoogle Scholar
  27. 27.
    Thiele H, Lauer B, Hambrecht R, et al.: Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001, 104:2917–2922.PubMedCrossRefGoogle Scholar
  28. 28.
    Thiele H, Sick P, Boudriot E, et al.: Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005, 26:1276–1283.PubMedCrossRefGoogle Scholar
  29. 29.
    Henriques JP, Remmelink M, Baan J, Jr, et al.: Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol 2006, 97:990–992.PubMedCrossRefGoogle Scholar
  30. 30.
    Remmelink M, Sjauw KD, Henriques JP, et al.: Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheter Cardiovasc Interv 2007, 70:532–537.PubMedCrossRefGoogle Scholar
  31. 31.
    Haithcock BE, Morita H, Fanous NH, et al.: Hemodynamic unloading of the failing left ventricle using an arterial-to-arterial extracorporeal flow circuit. Ann Thorac Surg 2004, 77:158–163.PubMedCrossRefGoogle Scholar
  32. 32.
    Konstam MA, Czerska B, Bohm M, et al.: Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation 2005, 112:3107–3114.PubMedCrossRefGoogle Scholar
  33. 33.
    Gharib M, Beizaie M: Correlation between negative near-wall shear stress in human aorta and various stages of congestive heart failure. Ann Biomed Eng 2003, 31:678–685.PubMedCrossRefGoogle Scholar
  34. 34.
    Frazier OH, Rose EA, McCarthy P, et al.: Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995, 222:327–336; discussion 336–338.PubMedCrossRefGoogle Scholar
  35. 35.
    Ashton RC, Jr, Goldstein DJ, Rose EA, et al.: Duration of left ventricular assist device support affects transplant survival. J Heart Lung Transplant 1996, 15:1151–1157.PubMedGoogle Scholar
  36. 36.
    Rao V, Oz MC, Flannery MA, et al.: Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003, 125:855–862.PubMedCrossRefGoogle Scholar
  37. 37.
    Lietz K, Long JW, Kfoury AG, et al.: Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007, 116:497–505.PubMedCrossRefGoogle Scholar
  38. 38.
    Rogers JG, Butler J, Lansman SL, et al.: Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007, 50:741–747.PubMedCrossRefGoogle Scholar
  39. 39.
    Dowling RD, Gray LA, Jr, Etoch SW, et al.: Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg 2004, 127:131–141.PubMedCrossRefGoogle Scholar
  40. 40.
    Copeland JG, Smith RG, Arabia FA, et al.: Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004, 351:859–867.PubMedCrossRefGoogle Scholar
  41. 41.
    Goldstein DJ: Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation. Circulation 2003, 108(Suppl 1):II272–II277.PubMedGoogle Scholar
  42. 42.
    Miller LW, Pagani FD, Russell SD, et al.: Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007, 357:885–896.PubMedCrossRefGoogle Scholar
  43. 43.
    Siegenthaler MP, Martin J, Pernice K, et al.: The Jarvik 2000 is associated with less infections than the HeartMate left ventricular assist device. Eur J Cardiothorac Surg 2003, 23:748–754; discussion 754–755.PubMedCrossRefGoogle Scholar
  44. 44.
    Frazier OH, Myers TJ, Westaby S, Gregoric ID: Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: physiologic implications and their relationship to patient selection. Ann Thorac Surg 2004, 77:133–142.PubMedCrossRefGoogle Scholar
  45. 45.
    Loree HM, Bourque K, Gernes DB, et al.: The Heartmate III: design and in vivo studies of a maglev centrifugal left ventricular assist device. Artif Organs 2001, 25:386–391.PubMedCrossRefGoogle Scholar
  46. 46.
    Hernandez AF, Grab JD, Gammie JS, et al.: A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons’ National Cardiac Database. Circulation 2007, 116:606–612.PubMedCrossRefGoogle Scholar
  47. 47.
    Deng MC, Edwards LB, Hertz MI, et al.: Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report-2005. J Heart Lung Transplant 2005, 24:1182–1187.PubMedCrossRefGoogle Scholar
  48. 48.
    Ochiai Y, McCarthy PM, Smedira NG, et al.: Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002, 106:1198–1202.Google Scholar
  49. 49.
    Fukamachi K, McCarthy PM, Smedira NG, et al.: Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999, 68:2181–2184.PubMedCrossRefGoogle Scholar
  50. 50.
    Simon D, Fischer S, Grossman A, et al.: Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005, 40:1108–1115.PubMedCrossRefGoogle Scholar
  51. 51.
    Argenziano M, Catanese KA, Moazami N, et al.: The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997, 16:822–831.PubMedGoogle Scholar
  52. 52.
    Korfer R, El-Banayosy A, Arusoglu L, et al.: Single-center experience with the thoratec ventricular assist device. J Thorac Cardiovasc Surg 2000, 119:596–600.PubMedCrossRefGoogle Scholar
  53. 53.
    Lazar RM, Shapiro PA, Jaski BE, et al.: Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 2004, 109:2423–2427.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Andreas Brieke
    • 1
  • Joseph ClevelandJr
  • JoAnn Lindenfeld
  1. 1.Division of CardiologyUniversity of Colorado at Denver and Health Sciences CenterAuroraUSA

Personalised recommendations